Subscribe
pfizer_istock-458618835_no_limit_pictures--2
no_limit_pictures / iStockphoto.com
31 July 2018Americas

Pfizer expects $1.9bn loss due to patent expirations

US-based pharmaceutical company  Pfizer today reported an increase in year-on-year revenue for the second quarter but projected nearly a $2 billion loss in 2018 due to patent expirations.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Sun Pharma takes Pfizer to court over Lyrica
8 April 2019   India-based drugmaker Sun Pharma has accused Pfizer of infringing a patent with a new extended-release formulation of Lyrica.
Big Pharma
Pfizer revenues to slow as drugs lose exclusivity
31 January 2019   American pharmaceutical company Pfizer warned investors of little revenue growth to come in 2019, owing partly to expiring exclusivity rights on drugs including Viagra and the seizure medicine Lyrica.
Big Pharma
Pfizer secures six-month Lyrica extension in US
29 November 2018   The US Food and Drug Administration has granted Pfizer paediatric exclusivity for Lyrica, extending the period of US market exclusivity for the drug by six months.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Sun Pharma takes Pfizer to court over Lyrica
8 April 2019   India-based drugmaker Sun Pharma has accused Pfizer of infringing a patent with a new extended-release formulation of Lyrica.
Big Pharma
Pfizer revenues to slow as drugs lose exclusivity
31 January 2019   American pharmaceutical company Pfizer warned investors of little revenue growth to come in 2019, owing partly to expiring exclusivity rights on drugs including Viagra and the seizure medicine Lyrica.
Big Pharma
Pfizer secures six-month Lyrica extension in US
29 November 2018   The US Food and Drug Administration has granted Pfizer paediatric exclusivity for Lyrica, extending the period of US market exclusivity for the drug by six months.

More on this story

Americas
Sun Pharma takes Pfizer to court over Lyrica
8 April 2019   India-based drugmaker Sun Pharma has accused Pfizer of infringing a patent with a new extended-release formulation of Lyrica.
Big Pharma
Pfizer revenues to slow as drugs lose exclusivity
31 January 2019   American pharmaceutical company Pfizer warned investors of little revenue growth to come in 2019, owing partly to expiring exclusivity rights on drugs including Viagra and the seizure medicine Lyrica.
Big Pharma
Pfizer secures six-month Lyrica extension in US
29 November 2018   The US Food and Drug Administration has granted Pfizer paediatric exclusivity for Lyrica, extending the period of US market exclusivity for the drug by six months.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB